SEC Form 4 · accession 0001104659-18-042320
Adaptimmune Therapeutics PLC · ADAP
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Charles Elliott Sigal
Director
Period of report
Jun 22, 2018
Accepted (ET)
Jun 26, 2018 · 5:00 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001621227
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Option to purchase Ordinary SharesF1 | $2.18 | Jun 22, 2018 | A | 154,809 | A | Jun 22, 2019 | Jun 22, 2028 | Ordinary Shares | 154,809 | 154,809 | D |
Explanation of responses
- F1The exercise price was converted from GBP1.65 based on an exchange rate of $U.S. 1.3250 to GBP1.00. The actual exercise price will be the pounds sterling amount.